Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

NCT00350623 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)
BIOLOGICAL: MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)
BIOLOGICAL: MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)

Sponsor

Merck Sharp & Dohme LLC